Hemophilia Treatment Drugs Market

Hemophilia Treatment Drugs Market (Product: Recombinant Coagulation Factor Concentrates, Plasma-derived Coagulation Factor Concentrates, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

Global Hemophilia Treatment Drugs Market Outlook 2031

  • The global industry was valued at US$ 11.8 Bn in 2022
  • It is estimated to grow at a CAGR of 5.0% from 2023 to 2031 and reach US$ 18.6 Bn by the end of 2031

Analyst Viewpoint

R&D of new medications and rise in demand for long-acting novel non-replacement therapies are expected to propel the hemophilia treatment drugs market size during the forecast period. Surge in diagnosis for hemophilia is also boosting demand for hemophilia treatment drugs.

R&D of personalized approaches in hemophilia treatment is likely to offer lucrative opportunities to vendors in the global hemophilia treatment drugs industry. Government bodies in various countries are funding the R&D of new drugs to reduce the burden of hemophilia. Anti-TFPI medications are gaining traction among patients as these medications aim to lower the mechanism that prevents blood from clotting excessively.

Hemophilia Treatment Drugs Market

Market Introduction

Hemophilia is an inherited bleeding illness. A person's blood does not clot effectively with this disease, which causes a variety of issues such as spontaneous bleeding. Hemophilia is most common among men. Hemophilia treatment drugs are pharmaceuticals that have been authorized by relevant regulatory bodies for the treatment of hemophilia. According to the Centers for Disease Control and Prevention (CDC), around 400 newborns in the U.S. are born with hemophilia A. According to the CDC report, about 33,000 men in the U.S. suffered from the disease. Thus, increase in cases of hemophilia is expected to spur the hemophilia treatment drugs market growth in the near future.

R&D of New Medications

Research activities play a vital role in the hemophilia treatment drugs market value. Most hemophilia treatment drug manufacturers are investing heavily in these activities for the development of new formulations that are beneficial for the treatment of hemophilia.

Anti-TFPI is a novel hemophilia medication that aims to minimize bleeding by lowering (or slowing) the mechanism that prevents blood from clotting excessively. Anti-TFPI restores hemostatic equilibrium by inhibiting the function of one of the anticoagulants, TFPI. Since anticoagulants prevent clotting, interfering with how they function causes clotting to occur. Anti-TFPI is not based on the replacement of a specific clotting protein, such as factor VIII(8) or factor IX(9). As a result, this medication for hemophilia can be used to reduce bleeding episodes in patients with both hemophilia A and hemophilia B. Anti-TFPI clinical studies are now in phase 3.

RNA Interference (RNAi) treatment targets an anticoagulant, antithrombin. It is a new treatment that aims to restore hemostatic equilibrium by lowering antithrombin levels, allowing enough thrombin, a coagulant, to develop to prevent bleeding. It can be used to reduce bleeding episodes in both hemophilia A and hemophilia B since it does not rely on replacing a specific clotting protein, such as factor VIII(8) or factor IX(9). RNA interference is now in phase 3 clinical studies.

Rise in Demand for Long-acting Novel Non-replacement Therapies Boosting Hemophilia Treatment Drugs Market Development

Novel non-replacement therapies for hemophilia A and B work by inhibiting the major natural anticoagulant antithrombin, which functions by inactivating activated factor X (FX) and thrombin. The suppression of antithrombin production by hepatocytes is accomplished by the use of RNA interference (RNAi), a natural method of gene silencing found in plants and humans. Fitusiran is an experimental small interfering RNA (siRNA) that inhibits antithrombin production in hepatocytes, restoring adequate hemostasis in people with hemophilia A or B. Fitusiran is now being studied in individuals with or without inhibitors as prophylaxis given subcutaneously every other month or once a month.

Another hemophilia therapy involves interfering with activated protein C (aPC). The thrombin-thrombomodulin complex activates PC to generate aPC, which inactivates FVIIIa and FVa de collaboration with its cofactor protein S, preventing further thrombin generation. These cause the prothrombinase and tenase-complex activities to be inactivated.

Inhibiting aPC may help restore hemostatic equilibrium in hemophilia patients by delaying thrombin production. SerpinPC is an aPC inhibitor that is now being tested in a proof-of-concept experiment in patients with severe hemophilia A and B. This modified serpin forms a covalent connection with aPC but not with a nonactivated PC and does not block thrombin. The absence of reported thrombotic events in clinical trials as of yet may be explained by the intact function of secondary aPC. These are key developments bolstering the hemophilia treatment drugs market progress.

High Demand for Recombinant Coagulation Factor Concentrates

According to the latest hemophilia treatment drugs market trends, the recombinant coagulation factor concentrates product segment is expected to dominate the industry during the forecast period. R&D of new recombinant drugs and gene therapies, such as Fitusiran (phase III trials) and valoctocogene roxaparvovec (phase III candidate), is boosting the segment.

Regional Outlook

According to the latest hemophilia treatment drugs market forecast, North America is anticipated to hold largest share from 2023 to 2031. Rise in prevalence of hemophilia is fueling the market dynamics of the region. According to the Centers for Disease Control and Prevention (CDC), hemophilia A affects one in every 5,000 male births. Increase in funding for hemophilia treatment is boosting the hemophilia treatment drugs industry statistics.

Many Hemophilia Treatment Centers (HTCs) in the U.S. are housed in large university medical and research facilities. More than 100 HTCs are funded by the federal government. Medical specialists at these HTCs give treatment, education, and support. Patients who receive care and treatment at HTCs generally have a lower risk of hospitalization and bleeding problems than those who receive care elsewhere.

The industry in Asia Pacific is projected to grow at the fastest rate during the forecast period. Rise in adoption of recombinant coagulation factor concentrates in developing countries, such as India and China, is augmenting the hemophilia treatment drugs market expansion in the region. The market in Latin America is poised to grow at a moderate pace during the forecast period.

Analysis of Key Players

Most hemophilia treatment drug companies are investing in R&D activities to expand their product portfolio. They are also adopting partnership, collaboration, and M&A strategies to increase their hemophilia treatment drugs market share.

Pfizer Inc., CSL Behring, Kedrion, Takeda Pharmaceutical Company Limited, Novo Nordisk A/S, Bayer AG, F. Hoffmann-La Roche Ltd., Octapharma AG, Biotest AG, and Sanofi S.A. are key entities operating in this market.

These companies have been profiled in the hemophilia treatment drugs market report based on parameters such as company overview, business strategies, financial overview, product portfolio, and business segments.

Key Developments in Hemophilia Treatment Drugs Market

  • In February 2023, The U.S. Food and Drug Administration (FDA) approved Sanofi’s ALTUVIIIO [Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein-ehtl], previously referred to as efanesoctocog alfa, a first-in-class, high-sustained factor VIII replacement therapy. ALTUVIIIO is indicated for routine prophylaxis and on-demand treatment to control bleeding episodes, as well as perioperative management (surgery) for adults and children with hemophilia A.
  • In February 2020, Novo Nordisk launched ESPEROCT, the company’s long-acting recombinant factor VIII product for the prevention and treatment of bleeding in individuals with hemophilia A

Hemophilia Treatment Drugs Market Snapshot

Attribute Detail
Market Value in 2022 (Base Year) US$ 11.8 Bn
Market Forecast Value in 2031 US$ 18.6 Bn
Growth Rate (CAGR) 5.0%
Forecast Period 2023-2031
Historical Data Available for 2020-2021
Quantitative Units US$ Bn for Value
Market Analysis Qualitative analysis includes drivers, restraints, opportunities, key trends, key market indicators, Porter’s Five Forces analysis, value chain analysis, and SWOT analysis. Furthermore, at the regional level, the qualitative analysis includes key trends, price trends, and key supplier analysis.
Competition Landscape
  • Prominent Players – Competition Dashboard and Revenue Share Analysis, 2023
  • Company Profiles (Details – Company Overview, Sales Area/Geographical Presence, Revenue, Strategy & Business Overview)
Format Electronic (PDF) + Excel
Regions Covered
  • North America
  • Latin America
  • Asia Pacific
  • Europe
  • Middle East & Africa
Countries Covered
  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Russia and CIS
  • Japan
  • China
  • India
  • ASEAN
  • Brazil
  • Mexico
  • GCC
  • South Africa
Market Segmentation
  • Product
    • Recombinant Coagulation Factor Concentrates
      • Factor VIII
      • Factor IX
      • Others
    • Plasma-derived Coagulation Factor Concentrates
      • Factor VIII
      • Factor IX
      • Others
    • Others
  • Disease Indication
    • Hemophilia A
    • Hemophilia B
    • Others
  • Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
Companies Profiled
  • Pfizer Inc.
  • CSL Behring
  • Kedrion
  • Takeda Pharmaceutical Company Limited
  • Novo Nordisk A/S
  • Bayer AG
  • F. Hoffmann-La Roche Ltd.
  • Octapharma AG
  • Biotest AG
  • Sanofi S.A.
Customization Scope Available upon Request
Pricing Available upon Request

Frequently Asked Questions

How big was the hemophilia treatment drugs market in 2022?

It was valued at US$ 11.8 Bn in 2022

How is the hemophilia treatment drugs business expected to grow by 2031?

It is likely to grow at a CAGR of 5.0% from 2023 to 2031

What are the key factors driving the demand for hemophilia treatment drugs?

R&D of new medications and rise in demand for long-acting novel non-replacement therapies

Which product segment held the largest share in the hemophilia treatment drugs industry?

The recombinant coagulation factor concentrates product segment held largest share in 2022

Which was the major region in the hemophilia treatment drugs landscape in 2022?

North America held largest share in 2022

Who are the key hemophilia treatment drug manufacturers?

Pfizer Inc., CSL Behring, Kedrion, Takeda Pharmaceutical Company Limited, Novo Nordisk A/S, Bayer AG, F. Hoffmann-La Roche Ltd., Octapharma AG, Biotest AG, and Sanofi S.A.

    1. Executive Summary

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Global Hemophilia Treatment Drugs Market

    4. Market Overview

        4.1. Market Segmentation

            4.1.1. Segment Definition

            4.1.2. Industry Evolution / Developments

        4.2. Overview

        4.3. Market Dynamics

            4.3.1. Drivers

            4.3.2. Restraints

            4.3.3. Opportunities

        4.4. Global Hemophilia Treatment Drugs Market Analysis and Forecast, 2023-2031

    5. Key Insights

        5.1. Pipeline Analysis

        5.2. List of Types of Hemophilia Treatment Drugs

        5.3. Disease Prevalence & Incidence Rate Globally with Key Countries

        5.4. COVID-19 Pandemic Impact on Industry

    6. Global Hemophilia Treatment Drugs Market Analysis and Forecast, by Product

        6.1. Introduction and Definitions

        6.2. Key Findings/Developments

        6.3. Market Value Forecast, by Product, 2023–2031

            6.3.1. Recombinant Coagulation Factor Concentrates

                6.3.1.1. Factor VIII

                6.3.1.2. Factor IX

                6.3.1.3. Others

            6.3.2. Plasma-derived Coagulation Factor Concentrates

                6.3.2.1. Factor VIII

                6.3.2.2. Factor IX

                6.3.2.3. Others

            6.3.3. Others

        6.4. Market Attractiveness, by Product

    7. Global Hemophilia Treatment Drugs Market Analysis and Forecast, by Disease Indication

        7.1. Introduction and Definitions

        7.2. Key Findings/Developments

        7.3. Market Value Forecast, by Disease Indication, 2023–2031

            7.3.1. Hemophilia A

            7.3.2. Hemophilia B

            7.3.3. Others

        7.4. Market Attractiveness, by Disease Indication

    8. Global Hemophilia Treatment Drugs Market Analysis and Forecast, by Distribution Channel

        8.1. Introduction and Definitions

        8.2. Key Findings/Developments

        8.3. Market Value Forecast, by Distribution Channel, 2023–2031

            8.3.1. Hospital Pharmacies

            8.3.2. Retail Pharmacies

            8.3.3. Online Pharmacies

        8.4. Market Attractiveness, by Distribution Channel

    9. Global Hemophilia Treatment Drugs Market Analysis and Forecast, by Region

        9.1. Key Findings

        9.2. Market Value Forecast, by Region, 2023–2031

            9.2.1. North America

            9.2.2. Europe

            9.2.3. Asia Pacific

            9.2.4. Latin America

            9.2.5. Middle East & Africa

        9.3. Market Attractiveness, by Region

    10. North America Hemophilia Treatment Drugs Market Analysis and Forecast

        10.1. Introduction

            10.1.1. Key Findings

        10.2. Market Value Forecast, by Product, 2023–2031

            10.2.1. Recombinant Coagulation Factor Concentrates

                10.2.1.1. Factor VIII

                10.2.1.2. Factor IX

                10.2.1.3. Others

            10.2.2. Plasma-derived Coagulation Factor Concentrates

                10.2.2.1. Factor VIII

                10.2.2.2. Factor IX

                10.2.2.3. Others

            10.2.3. Others

        10.3. Market Attractiveness, by Product

        10.4. Market Value Forecast, by Disease Indication, 2023–2031

            10.4.1. Hemophilia A

            10.4.2. Hemophilia B

            10.4.3. Others

        10.5. Market Attractiveness, by Disease Indication

        10.6. Market Value Forecast, by Distribution Channel, 2023–2031

            10.6.1. Hospital Pharmacies

            10.6.2. Retail Pharmacies

            10.6.3. Online Pharmacies

        10.7. Market Attractiveness, by Distribution Channel

        10.8. Market Value Forecast, by Country, 2023–2031

            10.8.1. U.S.

            10.8.2. Canada

        10.9. Market Attractiveness Analysis

            10.9.1. By Product

            10.9.2. By Disease Indication

            10.9.3. By Distribution Channel

            10.9.4. By Country

    11. Europe Hemophilia Treatment Drugs Market Analysis and Forecast

        11.1. Introduction

            11.1.1. Key Findings

            11.1.2. Recombinant Coagulation Factor Concentrates

                11.1.2.1. Factor VIII

                11.1.2.2. Factor IX

                11.1.2.3. Others

            11.1.3. Plasma-derived Coagulation Factor Concentrates

                11.1.3.1. Factor VIII

                11.1.3.2. Factor IX

                11.1.3.3. Others

            11.1.4. Others

        11.2. Market Attractiveness, by Product

        11.3. Market Value Forecast, by Disease Indication, 2023–2031

            11.3.1. Hemophilia A

            11.3.2. Hemophilia B

            11.3.3. Others

        11.4. Market Attractiveness, by Disease Indication

        11.5. Market Value Forecast, by Distribution Channel, 2023–2031

            11.5.1. Hospital Pharmacies

            11.5.2. Retail Pharmacies

            11.5.3. Online Pharmacies

        11.6. Market Attractiveness, by Distribution Channel

        11.7. Market Value Forecast, by Country/Sub-region, 2023–2031

            11.7.1. Germany

            11.7.2. U.K.

            11.7.3. France

            11.7.4. Italy

            11.7.5. Spain

            11.7.6. Rest of Europe

        11.8. Market Attractiveness Analysis

            11.8.1. By Product

            11.8.2. By Disease Indication

            11.8.3. By Distribution Channel

            11.8.4. By Country/Sub-region

    12. Asia Pacific Hemophilia Treatment Drugs Market Analysis and Forecast

        12.1. Introduction

            12.1.1. Key Findings

        12.2. Market Value Forecast, by Product, 2023–2031

            12.2.1. Recombinant Coagulation Factor Concentrates

                12.2.1.1. Factor VIII

                12.2.1.2. Factor IX

                12.2.1.3. Others

            12.2.2. Plasma-derived Coagulation Factor Concentrates

                12.2.2.1. Factor VIII

                12.2.2.2. Factor IX

                12.2.2.3. Others

            12.2.3. Others

        12.3. Market Attractiveness, by Product

        12.4. Market Value Forecast, by Disease Indication, 2023–2031

            12.4.1. Hemophilia A

            12.4.2. Hemophilia B

            12.4.3. Others

        12.5. Market Attractiveness, by Disease Indication

        12.6. Market Value Forecast, by Distribution Channel, 2023–2031

            12.6.1. Hospital Pharmacies

            12.6.2. Retail Pharmacies

            12.6.3. Online Pharmacies

        12.7. Market Attractiveness, by Distribution Channel

        12.8. Market Value Forecast, by Country/Sub-region, 2023–2031

            12.8.1. China

            12.8.2. Japan

            12.8.3. India

            12.8.4. Australia & New Zealand

            12.8.5. Rest of Asia Pacific

        12.9. Market Attractiveness Analysis

            12.9.1. By Product

            12.9.2. By Disease Indication

            12.9.3. By Distribution Channel

            12.9.4. By Country/Sub-region

    13. Latin America Hemophilia Treatment Drugs Market Analysis and Forecast

        13.1. Introduction

            13.1.1. Key Findings

        13.2. Market Value Forecast, by Product, 2023–2031

            13.2.1. Recombinant Coagulation Factor Concentrates

                13.2.1.1. Factor VIII

                13.2.1.2. Factor IX

                13.2.1.3. Others

            13.2.2. Plasma-derived Coagulation Factor Concentrates

                13.2.2.1. Factor VIII

                13.2.2.2. Factor IX

                13.2.2.3. Others

            13.2.3. Others

        13.3. Market Attractiveness, by Product

        13.4. Market Value Forecast, by Disease Indication, 2023–2031

            13.4.1. Hemophilia A

            13.4.2. Hemophilia B

            13.4.3. Others

        13.5. Market Attractiveness, by Disease Indication

        13.6. Market Value Forecast, by Distribution Channel, 2023–2031

            13.6.1. Hospital Pharmacies

            13.6.2. Retail Pharmacies

            13.6.3. Online Pharmacies

        13.7. Market Attractiveness, by Distribution Channel

        13.8. Market Value Forecast, by Country/Sub-region, 2023–2031

            13.8.1. Brazil

            13.8.2. Mexico

            13.8.3. Rest of Latin America

        13.9. Market Attractiveness Analysis

            13.9.1. By Product

            13.9.2. By Disease Indication

            13.9.3. By Distribution Channel

            13.9.4. By Country/Sub-region

    14. Middle East & Africa Hemophilia Treatment Drugs Market Analysis and Forecast

        14.1. Introduction

            14.1.1. Key Findings

        14.2. Market Value Forecast, by Product, 2023–2031

            14.2.1. Recombinant Coagulation Factor Concentrates

                14.2.1.1. Factor VIII

                14.2.1.2. Factor IX

                14.2.1.3. Others

            14.2.2. Plasma-derived Coagulation Factor Concentrates

                14.2.2.1. Factor VIII

                14.2.2.2. Factor IX

                14.2.2.3. Others

            14.2.3. Others

        14.3. Market Attractiveness, by Product

        14.4. Market Value Forecast, by Disease Indication, 2023–2031

            14.4.1. Hemophilia A

            14.4.2. Hemophilia B

            14.4.3. Others

        14.5. Market Attractiveness, by Disease Indication

        14.6. Market Value Forecast, by Distribution Channel, 2023–2031

            14.6.1. Hospital Pharmacies

            14.6.2. Retail Pharmacies

            14.6.3. Online Pharmacies

        14.7. Market Attractiveness, by Distribution Channel

        14.8. Market Value Forecast, by Country/Sub-region, 2023–2031

            14.8.1. GCC Countries

            14.8.2. South Africa

            14.8.3. Rest of Middle East & Africa

        14.9. Market Attractiveness Analysis

            14.9.1. By Product

            14.9.2. By Disease Indication

            14.9.3. By Distribution Channel

            14.9.4. By Country/Sub-region

    15. Competition Landscape

        15.1. Market Player – Competition Matrix (By Tier and Size of Companies)

        15.2. Market Share Analysis, by Company (2022)

        15.3. Company Profiles

            15.3.1. Pfizer Inc.

                15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.1.2. Product Portfolio

                15.3.1.3. Financial Overview

                15.3.1.4. SWOT Analysis

                15.3.1.5. Strategic Overview

            15.3.2. CSL Behring

                15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.2.2. Product Portfolio

                15.3.2.3. Financial Overview

                15.3.2.4. SWOT Analysis

                15.3.2.5. Strategic Overview

            15.3.3. Kedrion

                15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.3.2. Product Portfolio

                15.3.3.3. Financial Overview

                15.3.3.4. SWOT Analysis

                15.3.3.5. Strategic Overview

            15.3.4. Takeda Pharmaceutical Company Limited

                15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.4.2. Product Portfolio

                15.3.4.3. Financial Overview

                15.3.4.4. SWOT Analysis

                15.3.4.5. Strategic Overview

            15.3.5. Novo Nordisk A/S

                15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.5.2. Product Portfolio

                15.3.5.3. Financial Overview

                15.3.5.4. SWOT Analysis

                15.3.5.5. Strategic Overview

            15.3.6. Bayer AG

                15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.6.2. Product Portfolio

                15.3.6.3. Financial Overview

                15.3.6.4. SWOT Analysis

                15.3.6.5. Strategic Overview

            15.3.7. F. Hoffmann-La Roche Ltd.

                15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.7.2. Product Portfolio

                15.3.7.3. Financial Overview

                15.3.7.4. SWOT Analysis

                15.3.7.5. Strategic Overview

            15.3.8. Octapharma AG

                15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.8.2. Product Portfolio

                15.3.8.3. Financial Overview

                15.3.8.4. SWOT Analysis

                15.3.8.5. Strategic Overview

            15.3.9. Biotest AG

                15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.9.2. Product Portfolio

                15.3.9.3. Financial Overview

                15.3.9.4. SWOT Analysis

                15.3.9.5. Strategic Overview

            15.3.10. Sanofi S.A.

                15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.10.2. Product Portfolio

                15.3.10.3. Financial Overview

                15.3.10.4. SWOT Analysis

                15.3.10.5. Strategic Overview

    List of Tables

    Table 1: Global Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, by Product, 2023–2031

    Table 2: Global Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, by Disease Indication, 2023–2031

    Table 3: Global Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, by Distribution Channel, 2023–2031

    Table 4: Global Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, by Region, 2023–2031

    Table 5: North America Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, by Country, 2023–2031

    Table 6: North America Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, by Product, 2023–2031

    Table 7: North America Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, by Disease Indication, 2023–2031

    Table 8: North America Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, by Distribution Channel, 2023–2031

    Table 9: Europe Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, by Country/Sub-region, 2023–2031

    Table 10: Europe Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, by Product, 2023–2031

    Table 11: Europe Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, by Disease Indication, 2023–2031

    Table 12: Europe Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, by Distribution Channel 2023–2031

    Table 13: Asia Pacific Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, by Country/Sub-region, 2023–2031

    Table 14: Asia Pacific Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, by Product, 2023–2031

    Table 15: Asia Pacific Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, by Disease Indication, 2023–2031

    Table 16: Asia Pacific Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, by Distribution Channel, 2023–2031

    Table 17: Latin America Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, by Country/Sub-region, 2023–2031

    Table 18: Latin America Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, by Product, 2023–2031

    Table 19: Latin America Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, by Disease Indication, 2023–2031

    Table 20: Latin America Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, by Distribution Channel 2023–2031

    Table 21: Middle East & Africa Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, by Country/Sub-region, 2023–2031

    Table 22: Middle East & Africa Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, by Product, 2023–2031

    Table 23: Middle East & Africa Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, by Disease Indication, 2023–2031

    Table 24: Middle East & Africa Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, by Distribution Channel 2023–2031

    List of Figures

    Figure 1: Global Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, 2023–2031

    Figure 2: Global Hemophilia Treatment Drugs Market Value Share, by Product, 2022

    Figure 3: Global Hemophilia Treatment Drugs Market Value Share, by Disease Indication, 2022

    Figure 4: Global Hemophilia Treatment Drugs Market Value Share, by Distribution Channel, 2022

    Figure 5: Global Hemophilia Treatment Drugs Market Value Share Analysis, by Product, 2022 and 2031

    Figure 6: Global Hemophilia Treatment Drugs Market Attractiveness Analysis, by Product, 2023–2031

    Figure 7: Global Hemophilia Treatment Drugs Market Value Share Analysis, by Disease Indication, 2022 and 2031

    Figure 8: Global Hemophilia Treatment Drugs Market Attractiveness Analysis, by Disease Indication, 2023–2031

    Figure 9: Global Hemophilia Treatment Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031

    Figure 10: Global Hemophilia Treatment Drugs Market Attractiveness Analysis, by Distribution Channel 2023–2031

    Figure 11: Global Hemophilia Treatment Drugs Market Value Share Analysis, by Region, 2022 and 2031

    Figure 12: Global Hemophilia Treatment Drugs Market Attractiveness Analysis, by Region, 2023–2031

    Figure 13: North America Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, 2023–2031

    Figure 14: North America Hemophilia Treatment Drugs Market Value Share Analysis, by Country, 2022 and 2031

    Figure 15: North America Hemophilia Treatment Drugs Market Attractiveness Analysis, by Country, 2023–2031

    Figure 16: North America Hemophilia Treatment Drugs Market Value Share Analysis, by Product, 2022 and 2031

    Figure 17: North America Hemophilia Treatment Drugs Market Attractiveness Analysis, by Product, 2023–2031

    Figure 18: North America Hemophilia Treatment Drugs Market Value Share Analysis, by Disease Indication, 2022 and 2031

    Figure 19: North America Hemophilia Treatment Drugs Market Attractiveness Analysis, by Disease Indication, 2023–2031

    Figure 20: North America Hemophilia Treatment Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031

    Figure 21: North America Hemophilia Treatment Drugs Market Attractiveness Analysis, by Distribution Channel 2023–2031

    Figure 22: Europe Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, 2023–2031

    Figure 23: Europe Hemophilia Treatment Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

    Figure 24: Europe Hemophilia Treatment Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

    Figure 25: Europe Hemophilia Treatment Drugs Market Value Share Analysis, by Product, 2022 and 2031

    Figure 26: Europe America Hemophilia Treatment Drugs Market Attractiveness Analysis, by Product, 2023–2031

    Figure 27: Europe Hemophilia Treatment Drugs Market Value Share Analysis, by Disease Indication, 2022 and 2031

    Figure 28: Europe Hemophilia Treatment Drugs Market Attractiveness Analysis, by Disease Indication, 2023–2031

    Figure 29: Europe Hemophilia Treatment Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031

    Figure 30: Europe Hemophilia Treatment Drugs Market Attractiveness Analysis, by Distribution Channel 2023–2031

    Figure 31: Asia Pacific Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, 2023–2031

    Figure 32: Asia Pacific Hemophilia Treatment Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

    Figure 33: Asia Pacific Hemophilia Treatment Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

    Figure 34: Asia Pacific Hemophilia Treatment Drugs Market Value Share Analysis, by Product, 2022 and 2031

    Figure 35: Asia Pacific Hemophilia Treatment Drugs Market Attractiveness Analysis, by Product, 2023–2031

    Figure 36: Asia Pacific Hemophilia Treatment Drugs Market Value Share Analysis, by Disease Indication, 2022 and 2031

    Figure 37: Asia Pacific Hemophilia Treatment Drugs Market Attractiveness Analysis, by Disease Indication, 2023–2031

    Figure 38: Asia Pacific Hemophilia Treatment Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031

    Figure 39: Asia Pacific Hemophilia Treatment Drugs Market Attractiveness Analysis, by Distribution Channel 2023–2031

    Figure 40: Latin America Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, 2023–2031

    Figure 41: Latin America Hemophilia Treatment Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

    Figure 42: Latin America Hemophilia Treatment Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

    Figure 43: Latin America Hemophilia Treatment Drugs Market Value Share Analysis, by Product, 2022 and 2031

    Figure 44: Latin America Hemophilia Treatment Drugs Market Attractiveness Analysis, by Product, 2023–2031

    Figure 45: Latin America Hemophilia Treatment Drugs Market Value Share Analysis, by Disease Indication, 2022 and 2031

    Figure 46: Latin America Hemophilia Treatment Drugs Market Attractiveness Analysis, by Disease Indication, 2023–2031

    Figure 47: Latin America Hemophilia Treatment Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031

    Figure 48: Latin America Hemophilia Treatment Drugs Market Attractiveness Analysis, by Distribution Channel, 2023–2031

    Figure 49: Middle East & Africa Hemophilia Treatment Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

    Figure 50: Middle East & Africa Hemophilia Treatment Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

    Figure 51: Middle East & Africa America Hemophilia Treatment Drugs Market Value Share Analysis, by Product, 2023–2031

    Figure 52: Middle East & Africa America Hemophilia Treatment Drugs Market Attractiveness Analysis, by Product, 2023–2031

    Figure 53: Middle East & Africa Hemophilia Treatment Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031

    Figure 54: Middle East & Africa Hemophilia Treatment Drugs Market Attractiveness Analysis, by Distribution Channel 2023–2031

    Figure 55: Global Hemophilia Treatment Drugs Market Share Analysis, by Company (2022)

Copyright © Transparency Market Research, Inc. All Rights reserved